Oncolytic viruses: a new class of immunotherapy drugs
By H. Kaufman, F. Kohlhapp, A. Zloza. Nature reviews. Drug discovery, 2015
1,499 citations recorded by the source corpus.
Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity. The molecular and cellular mechanisms of action are not fully elucidated but are likely to depend on viral replication within transformed cells, induction of primary cell death, interaction with tumour cell antiviral elements and initiation of innate and adaptive anti-tumour immunity. A variety of native and genetically modified viruses have been developed as oncolytic agents, and the approval of the first oncolytic virus by the US Food and Drug Administration (FDA) is anticipated in the near future. This Review provides a comprehensive overview of the basic biology supporting oncolytic viruses as cancer therapeutic agents, describes oncolytic viruses in advanced clinical trials and discusses the unique challenges in the development of oncolytic viruses as a new class of drugs for the treatment of cancer.
Subfields: Genetics, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/91dbf3eed0524bc6806e86d1d2c57f4ab67b424e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “However, an initial host response to the virus may result in the rapid clearance of the virus before it manages to replicate and infect tumor cells at a magnitude that will ensure the initiation of an efficient vaccination response [28].”